IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.492,93 +15,67 (+0,03%)
Synovics Pharmaceuticals, Inc. (SYVC)
Synovics Pharmaceuticals, Inc.
5360 Northwest 35th Avenue
Fort Lauderdale, FL 33309
United States
954-486-4590
Sector(es):
Sector:
Empleados a tiempo completo: 155
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jyotindra R. Gange | Interim Principal Executive Officer & Director | N/A | N/A | 1949 |
| Mr. John R. Palmer | Chairman of InCon Technologies Inc.& Incon International Ltd. & CEO of InCon Technologies Inc | N/A | N/A | 1943 |
Descripción
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Gobierno corporativo
El ISS Governance QualityScore de Synovics Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
